Bynocs’ Post

I'm pleased to announce our latest study published in International Ophthalmology: "Canaloplasty via an ab-interno surgical technique in patients with primary angle-closure glaucoma (PACG)." Our findings highlight ab-interno canaloplasty as a safe and effective approach for #PACG—a glaucoma type traditionally not indicated for MIGS procedures. In PACG, canaloplasty achieved significant reductions in intraocular pressure (IOP) and lowered medication reliance, presenting an encouraging management option for this challenging glaucoma type. These findings may be particularly relevant for clinicians in Asia, where angle-closure glaucoma is more prevalent. For those interested in the details, I invite you to explore our research here: https://lnkd.in/db5ym4CX #GlaucomaResearch #Canaloplasty #MIGS #Ophthalmology #PACG #EyeCare #ClinicalOutcomes #glaucoma #angleclosure Springer Nature

Glaucoma stands as the leading cause of permanent vision loss, affecting approximately 80 million people in 2020, with projections indicating a rise to 112 million by 2040. * World Glaucoma Week is an opportunity to promote regular eye screenings for early diagnosis and treatment, as well as to tackle nonadherence in glaucoma patients to prevent irreversible blindness worldwide. Find out more about open angle glaucoma and things to know by watching this Viatris educational video. #WorldGlaucomaWeek #Glaucoma #GlaucomaTreatment #Ophthalmology #viaViatris *European Glaucoma Society Terminology and Guidelines for Glaucoma. 5th Edition British Journal of Ophthalmology.

🎥 Join Dr. Peter Kaiser as he delves into the significant advancements in ophthalmic treatment with the introduction of Bayer | Ophthalmology 8 mg aflibercept. Discover how this higher dosage is making strides in patient care, allowing for extended treatment intervals and improved outcomes, especially for those with challenging cases. Dr. Kaiser shares his experiences and the promising results observed in two distinct patient groups, showcasing the drug's versatility and effectiveness. Tune in to gain valuable insights into this groundbreaking development in ophthalmology! #COPHY2024 #Aflibercept8mg #OphthalmologyInnovation #PatientCareProgress #OphthalmologyResearch #PatientCare #HealthcareEducation #retina #OphthalmologyFuture #medicalinnovation #glaucoma #Surgicalretina #uveitis #neuropathy COPHy Congress

Longer patching therapy (more minutes of occlusion per day) is not associated with more parental stress or worsened behavioral outcomes in children with unilateral congenital cataract, according to a study published in JAMA Ophthalmology. Since less time patching can worsen visual outcomes in these patients, the report suggests that changes to the current guidelines of patching throughout the amblyogenic period are not necessary. Read more: https://brnw.ch/21wJOGX #PatchingTherapy #Occlusion #OcclusionTherapy #ParentalStress #BehavioralOutcomes #UnilateralCongenitalCataract #Cataract #BehavioralOutcomes #Optometry #EyeHealth #EyeCare #Amblyopia

🎥 Delve into the science of dosing with Dr. Peter Kaiser as he discusses the enhanced durability of Bayer | Ophthalmology 8 mg aflibercept. Learn how increasing the molar dose can extend the drug's half-life, offering tailored treatment intervals based on individual patient needs. Dr. Kaiser sheds light on the practical application of these findings, emphasizing the importance of a patient-centric approach in optimizing treatment outcomes. Explore the nuances of treat-and-extend paradigms with high-dose Eylea, and discover how personalized care is revolutionizing patient experiences in ophthalmology.  #COPHY2024 #Aflibercept8mg #OphthalmologyInnovation #PatientCareProgress #OphthalmologyResearch #PatientCare #HealthcareEducation #retina #OphthalmologyFuture #medicalinnovation #glaucoma #Surgicalretina #uveitis #neuropathy COPHy Congress Simrat Sodhi

Counting down to the Sally Letson Symposium, Sept 19-21. If pediatric ophthalmology and adult strabismus is your focus, this is where you'll find the latest insights and discussions. Learn more: cos-sco.ca/SLS2024 #Ophthalmology #PediatricOphthalmology #Ottawa #SallyLetson

Patients with neovascular #AgeRelatedMacularDegeneration (nAMD) undergoing treat-and-extend #Faricimab therapy can maintain vision gains through 2 years, according to investigators of 2 global phase 3 clinical trials published in Ophthalmology (American Academy of Ophthalmology). Approximately 80% of participants who were managed faricimab reached 12 week dosing or longer. This is significant as treat-and-extend-based personalized treatment interval (T&E-based PTI) most closely mirrors real-world practice, according to the report. Read more: https://brnw.ch/21wItuu #NeovascularAgedRelatedMacularDegeneration #nAMD #Faricimab #ClinicalTrials #Ophthalmology #EyeHealth #EyeCare #Ophthalmology

🌟 Dive into the insights of Dr. Anat Loewenstein as she discusses the findings of the Barometer Study - research made possible with the support of Bayer | Ophthalmology - a global survey aimed at understanding patient needs and healthcare practitioner awareness in ophthalmology. Discover the surprising revelations about clinic accessibility, staff knowledge gaps, and patient communication. Dr. Loewenstein's discussion sheds light on crucial areas needing attention in eye care, sparking conversations on how to enhance patient experience and staff education. Join us for this eye-opening session! #COPHY2024 #OphthalmologyResearch #PatientCare #HealthcareEducation #retina #OphthalmologyFuture #medicalinnovation #glaucoma #Surgicalretina #uveitis #neuropathy COPHy Congress Simrat Sodhi Anat Loewenstein Vision Academy

Did you know over 70,000 people in the UK are affected by glaucoma, and half are unaware they have it? This Glaucoma Awareness Week, we are raising awareness about the importance of managing glaucoma to prevent vision loss. At CHEC, we understand the pivotal role optometrists play in early detection and treatment. Our team provides comprehensive ophthalmology services, conducting over 1,300 glaucoma consultations weekly across our 25+ locations. We are committed to guiding your patients through every stage of their glaucoma journey with expert care and support. Discover more about our Glaucoma treatments here: https://lnkd.in/eMKiGJh4 #glaucomaawarenessweek #eyehealth #glaucomaweek #optometry #raisingawareness #glaucoma #glaucomatreatments #eyetreatments #earlydetection #ophthalmology #eyecare #patientcare #patienthealth #workingwiththeNHS #supportingtheNHS #ophthalmiccare #glaucomacare #healthawareness

Glaucoma stands as the leading cause of permanent vision loss, affecting approximately 80 million people in 2020, with projections indicating a rise to 112 million by 2040. * World Glaucoma Week is an opportunity to promote regular eye screenings for early diagnosis and treatment, as well as to tackle nonadherence in glaucoma patients to prevent irreversible blindness worldwide. Find out more about open angle glaucoma risk factors and treatment by watching this Viatris educational video. #worldglaucomaweek #Glaucoma #GlaucomaTreatment #Ophthalmology #viaViatris *European Glaucoma Society Terminology and Guidelines for Glaucoma. 5th Edition British Journal of Ophthalmology.